Last reviewed · How we verify

ON 01910.Na — Competitive Intelligence Brief

ON 01910.Na (ON 01910.Na) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: MDM2 inhibitor. Area: Oncology.

phase 3 MDM2 inhibitor MDM2 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

ON 01910.Na (ON 01910.Na) — Traws Pharma, Inc.. ON 01910.Na is a small molecule that targets the MDM2 protein.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
ON 01910.Na TARGET ON 01910.Na Traws Pharma, Inc. phase 3 MDM2 inhibitor MDM2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (MDM2 inhibitor class)

  1. Traws Pharma, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ON 01910.Na — Competitive Intelligence Brief. https://druglandscape.com/ci/on-01910-na. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing